Member Info for sphinx100

Looks to me they just want to keep below 10% !

Lots of tiny buys today ! Wonder if there’s a update somewhere!

In the context of developing a new product—particularly in the supplement, nutraceutical, or food industries—the material supplementation phase (often referred to as sourcing, material procurement, or ingredient QC) is the crucial stage where high-quality raw materials are identified, sourced, and validated before full-scale manufacturing.

Exim Pharma

Exim Pharma

+1

This phase ensures that the product’s formulation is effective, safe, compliant with regulations, and scalable.

I found this AI definition interesting –5x-15x+ Revenue: This is considered significant, often reserved for SaaS and high-growth technology companies with over 100% ARR growth and high net retention.

Top Tier: During peak markets, top-tier SaaS companies have commanded over 20x, but 10x–15x is considered a very strong, "significant" multiple in a normalized market.

Medium

Medium

+1

2. High-Growth Non-Tech/Service

3x–5x+ Revenue: A multiple of 3x or higher is significant for service-based businesses, digital media properties, or consumer products with strong brand loyalty and recurring customer revenue.

exitshub.com

exitshub.com

+1

3. Traditional Industries (Low vs. Significant)

Typical Multiple: 0.5x–1.5x (Manufacturing, Retail, Traditional Services).

Significant Multiple: For these industries, any multiple exceeding 2x is often considered significant, signaling high-profit margins or unique competitive advantages.

exitshub.com

exitshub.com

+1

Going to be a lot of ISA transfers this week ! Gives the MMs a chance to play their pathetic games I suppose .

I’m sort of expecting a raise ,just hope there’s not to much of a discount from this price , if they raised £1m for stock at 1p with a share issue we’re only looking at 100 million shares

Nope, it’s back down .

Nice rise today if it can hold on to it ,.

Yeah bit mixed up there, it was an AI opinion

Based on recent project assessments, 2,200 Mcf (thousand cubic feet) of helium is valued at approximately $1.5 million to over £4 million per month depending on the spot price and the grade of helium (crude vs. refined).

Projected Revenue (March 2026): Production of 2,200 Mcf per month is estimated to bring in roughly $2 million USD per month (approx. £1.5M) for refined helium, but can reach as high as £4 million per month during periods of high shortage and higher spot Price

From the report

The Pinon Canyon Plant is designed with a nameplate capacity of approximately 560,400 Mcf

of sales gas per annum, comprising 2,200 Mcf of helium and 44,500 Mcf of CO2 per month at

full capacity.

Yeah I’m buying a euro millions ticket tomorrow think I’ll have more chance of winning that .

Trading update or not !

I asked for a timeframe of approval.

Estimated Timeline and Process

Because this is the first-ever application for a completely new health function claim under China's 2023 "Implementation Rules," there is no exact historical precedent for the duration of the final stages. However, the following factors define the current timeline:

NutraIngredients.com

NutraIngredients.com

+1

Standard Review Duration: Traditional "Blue Hat" registrations for existing claims typically take 2 to 3 years to gain full approval. Having been submitted in August 2023, the Fruitflow application is approaching the 2.5-year mark.

Recent Milestones: In early 2025, reports indicated that the State Administration for Market Regulation (SAMR) had completed its first technical review for this type of claim, raising expectations for approvals to begin surfacing in 2025 or 2026.

Market Indicators: Provexis recently signaled "positive momentum" and is planning multiple production runs throughout 2026 to meet anticipated demand from BYHEALTH once the approval is secured.

New "Bone and Joint" Precedent: In January 2026, the SAMR officially added a new function for "bone and joint health" to the permitted catalog, marking the first successful addition since the 2023 rules were established. This suggests the regulatory "gridlock" for new functions has broken, clearing the path for the Fruitflow anti-platelet claim next

It sounds like a supply contract between Pxs and by-health for ff , can’t be sure as it needed translation and things don’t always come across well in English , it was in 2025 so we would have heard about it if it was important imo .

Ok just looked it up just another name for ByHealth co.

Who are Tanxin biogen ?

annual report out , mention for Provexis on pg 97

Any day now , of course there will be no revenue but an update of all that’s happening will be helpful in deciding investing strategies

So an increase of 50-200% spot price could completely change revenue from the Galactica project .Luckily they haven’t committed to a long term buyer as of Friday .

Sounds positive again ,could be this month !